Denver, July 29, 2016 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Qbrelis™ (Lisinopril) Oral Solution, the first and only FDA-approved Lisinopril oral solution. Qbrelis™ is indicated for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults.¹

Continue reading FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older →

Denver, October 26, 2016 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that Qbrelis™ (lisinopril) oral solution, the first and only FDA-approved lisinopril oral solution, is now available for ordering. Qbrelis™ is indicated for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction (heart attack) in adults.1

Continue reading Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older, is Now Available →

Denver, July 31, 2017 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leaders in the development and commercialization of innovative and safe medicines for children, today announced that Xatmep™ (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution, is now available for ordering. Xatmep is indicated for the treatment of acute lymphoblastic leukemia (ALL) and the management of polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients.

Continue reading Xatmep – The First and Only Ready-To-Use Methotrexate Oral Solution is Now Available →

Denver, January 10, 2017 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that EPANED® Oral Solution, the first and only FDA-approved enalapril oral solution, is now available for ordering. EPANED is an oral solution that enables consistent weight-based dosing for children over 1 month of age. EPANED reduces the potential for errors as a ready-to-use solution that does not require mixing. EPANED is indicated for the treatment of hypertension (high blood pressure) in adult and pediatric patients older than 1 month of age, treatment of symptomatic heart failure, and treatment of asymptomatic left ventricular dysfunction. 1

Continue reading EPANED® (enalapril maleate) Oral Solution 1 mg/mL, the First and Only FDA-Approved Enalapril Oral Solution for the Treatment of Pediatric Hypertension in Patients Older than 1 Month, is Now Available →

Silvergate Pharmaceuticals Inc. Enables Consistent Dosing For Children

Denver, 13 August 2013— Silvergate Pharmaceuticals Inc, focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned™ (enalapril maleate Powder for Oral Solution) to treat hypertension (high blood pressure) in people one month and older. Enalapril is one of the most commonly prescribed medicines in the United States to treat high blood pressure.

Continue reading FDA Approves Epaned, a Powder for a Liquid Form of Enalapril for Children and Adults →